title: TGF-β signaling and its targeting for glioma treatment.
abstract: Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine, secreted by a variety of cells including immune cells, tumor cells, and stromal cells. TGF-β signaling is dysregulated in cancer patients, and this aberrant signaling at least in part contributes to initiation and progression of many cancers including glioma. The dysregulated signaling components provide molecular targets for the treatment of glioma. In this article, we review TGF-β signaling and its targeting in glioma.
authors.affiliation: Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University Columbus, Ohio 43210, USA ; The Ohio State University Comprehensive Cancer Center Columbus, Ohio 43210, USA.
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Han
authors.affiliation: Department of Neurosurgery, Massachusetts General Hospital Boston, Massachusetts 02114, USA.
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Alvarez-Breckenridge
authors.affiliation: The Ohio State University Comprehensive Cancer Center Columbus, Ohio 43210, USA.
authors.forename: Qi-En
authors.initials: QE
authors.lastname: Wang
authors.affiliation: Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University Columbus, Ohio 43210, USA ; The Ohio State University Comprehensive Cancer Center Columbus, Ohio 43210, USA.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Yu
keywords: TGF-β; TGF-β signaling; glioma; glioma treatment; gliomagenesis